Cargando…

2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT Study

BACKGROUND: Multidrug resistant (MDR) Gram-negative bacteria, including metallo-β-lactamase (MBL) producers, pose significant treatment challenges. This study investigated efficacy and safety of aztreonam-avibactam (ATM-AVI) in the treatment of complicated intra-abdominal infection (cIAI) or hospita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carmeli, Yehuda, Cisneros, Jose-Miguel, Paul, Mical, Daikos, Georgios L, Wang, Minggui, Cisneros, Julian Torre, Singer, George, Titov, Ivan, Gumenchuk, Illia, Zhao, Yongjie, Jiménez Rodríguez, Rosa-María, Liang, Lu, Chen, Gang, Pyptiuk, Oleksandr, Aksoy, Firdevs, Rogers, Halley, Wible, Michele, Arhin, Francis, Luckey, Alison, Leaney, Joanne, Pypstra, Rienk, Chow, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676936/ http://dx.doi.org/10.1093/ofid/ofad500.2476

Ejemplares similares

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria
por: Emeraud, Cécile, et al.
Publicado: (2023)

In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
por: Wang, Wen, et al.
Publicado: (2021)

In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae
por: Huang, Yu-Shan, et al.
Publicado: (2023)

2443. Searching for the Optimal Treatment Regimen for Metallo-β-Lactamase Producing Enterobacteriaceae: Aztreonam Plus Ceftazidime–Avibactam vs. Aztreonam Plus Meropenem–Vaborbactam
por: Biagi, Mark, et al.
Publicado: (2018)

Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales
por: Kelley, C. J., et al.
Publicado: (2022)

1385. Efficacy of Ceftazidime–Avibactam in Combination with Aztreonam (COMBINE): Solutions for Metallo-β-Lactamase Producing-Enterobacteriaceae (MBL)
por: Lodise, Thomas P, et al.
Publicado: (2018)

A Case of New Delhi Metallo-β-Lactamases (NDM) Citrobacter sedlakii Osteomyelitis Successfully Treated With Ceftazidime-Avibactam and Aztreonam
por: Rubnitz, Zachary A, et al.
Publicado: (2022)

Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
por: Cornely, Oliver A, et al.
Publicado: (2020)

665. Modified Superposition in vitro Susceptibility of Aztreonam and Ceftazidime/Avibactam for an NDM-5 Metallo-β-Lactamase-Producing Klebsiella pneumoniae Isolate
por: Schmetterer, Justin, et al.
Publicado: (2022)

The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
por: Mauri, Carola, et al.
Publicado: (2021)

Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020
por: Bhatnagar, Amelia, et al.
Publicado: (2021)

2149. In vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenem-Resistant Enterobacterales With and Without Carbapenemases, ATLAS Global Surveillance Program, 2017–2021
por: Wise, Mark G, et al.
Publicado: (2023)

1567. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Multidrug-Resistant Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2016-2018
por: Kazmierczak, Krystyna, et al.
Publicado: (2020)

1717. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2020
por: Estabrook, Mark, et al.
Publicado: (2022)

2119. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2021
por: Estabrook, Mark, et al.
Publicado: (2023)

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Aztreonam-avibactam: an option against carbapenem-resistant Enterobacterales with emerging resistance
por: Wu, Shikai, et al.
Publicado: (2022)

Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter
por: Wu, Shikai, et al.
Publicado: (2023)

Factors associated with recruitment success in the phase 2a study of aztreonam–avibactam development programme: a descriptive qualitative analysis among sites in Spain
por: Jimenez-Rodriguez, Rosa M, et al.
Publicado: (2022)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
por: Yu, Wei, et al.
Publicado: (2021)

1720. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Urinary Tract Infections Collected During the ATLAS Global Surveillance Program, 2017-2020
por: Estabrook, Mark, et al.
Publicado: (2022)

1252. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Bloodstream Infections collected during the ATLAS Global Surveillance Program, 2015-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020
por: Piérard, Denis, et al.
Publicado: (2023)

2756. Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021)
por: Castanheira, Mariana, et al.
Publicado: (2023)

1225. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales Collected from Geriatric Patients in ICU and non-ICU wards, ATLAS Surveillance Program 2016-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

1265. In Vitro Activity of Aztreonam-Avibactam against Klebsiella pneumoniae Isolates Analyzed by Epidemic Lineage and Hypervirulence Factors Collected in China as Part of the ATLAS Global Surveillance Study in 2019
por: Estabrook, Mark, et al.
Publicado: (2021)

A Simple Disk Stacking Plus Micro-Elution Method for Rapid Detection of the Synergistic Effect of Aztreonam and Ceftazidime/Avibactam Against Metallo-β-Lactamase Producing Enterobacterales
por: Liu, Zhou, et al.
Publicado: (2023)

2747. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-β-Lactamase-Producing Enterobacterales collected through the Antimicrobial Resistance Laboratory Network, March 2019 to April 2023
por: Bhatnagar, Amelia, et al.
Publicado: (2023)

1231. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Lower Respiratory Tract Infections Collected During the ATLAS Global Surveillance Program, 2017-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

1422. Comparative Monte-Carlo Analysis of Aztreonam-Avibactam vs. Ceftazidime–Avibactam Against Carbapenem-Resistant Gram-Negative Pathogens
por: Smith, Aaron, et al.
Publicado: (2018)

In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant Enterobacterales Isolates from South Korea
por: Kim, Taeeun, et al.
Publicado: (2020)

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2021)

1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients
por: Sader, Helio S, et al.
Publicado: (2022)

Interaction of Avibactam with Class B Metallo-β-Lactamases
por: Abboud, Martine I., et al.
Publicado: (2016)

Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro
por: Lin, Qiuxia, et al.
Publicado: (2021)

In Vitro Evaluation of the Activity of Aztreonam-Avibactam against 341 Recent Clinical Isolates of Anaerobes
por: Snydman, David R., et al.
Publicado: (2021)

Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against Klebsiella pneumoniae by MALDI-TOF MS
por: Wilhelm, Camila Mörschbächer, et al.
Publicado: (2023)

In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-β-lactamase-producing Pseudomonas aeruginosa
por: Oie, Shigeharu, et al.
Publicado: (2009)

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates
por: Bae, Moonsuk, et al.
Publicado: (2021)

Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing Enterobacterales
por: Merad, Yanis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_636gg2cu9a2bev59oavsk9491c